Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma.

Formalin-fixed and paraffin-embedded lymph node biopsy specimens from 52 untreated patients with newly diagnosed diffuse large cell (n = 48) or mixed cell (n = 4) non-Hodgkin's lymphoma (NHL) were analyzed for DNA content and proliferative activity (PA) by flow cytometry. The results obtained by flow cytometry were compared with the results of cytogenetic studies performed on 28 of the specimens. The median age of the patients was 65 years (range, 15-84 years) and the male to female ratio was 3 to 2. All patients were uniformly staged and uniformly treated with cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone. The flow cytometric results were compared statistically by univariate analysis with the rate and duration of complete remission and survival. Tumors with low PA (greater than or equal to 80% of cells in G0/G1 phase) were found in 65% of the patients; 74% of those with low PA versus only 44% of those with high PA achieved an initial complete remission (P less than 0.02). DNA aneuploidy was detected in tumors of 56% of the patients and was associated with a significantly longer duration of complete remission (P less than 0.01). Both low PA and aneuploidy independently predicted longer survival. The predicted 2-year actuarial survival for patients with tumors with low PA was 68% versus 10% for those with high PA (P less than 0.01). Similarly, the 2-year survival of patients with aneuploid tumors was 60% versus 36% for those with diploid tumors (P less than 0.01). The combination of PA and DNA content categorized the patients into four groups with decreasing 2-year survivals: low PA/aneuploid (n = 20), 77%; low PA/diploid (n = 14), 57%; high PA/aneuploid (n = 9), 32%; high PA/diploid (n = 9), 0%. The flow cytometric results correlated well with those of the cytogenetic studies. We conclude that low PA and DNA aneuploidy, both separately and in combination, predict a favorable clinical outcome for patients with diffuse mixed cell and large cell NHL.

[1]  H. Olsson,et al.  Survival following combination chemotherapy in advanced high grade non‐Hodgkin's lymphomas: Relation to proliferative activity of the lymphoma cells , 1987, European journal of haematology.

[2]  J. Winter,et al.  Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. , 1986, Cancer research.

[3]  R. Camplejohn,et al.  Prognostic importance of DNA flow cytometry in non-Hodgkin's lymphomas. , 1986, Journal of clinical pathology.

[4]  D. Weisenburger,et al.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Taylor,et al.  Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. , 1985, Cytometry.

[6]  J. Srigley,et al.  Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry. , 1985, Blood.

[7]  Robert C. Leif,et al.  Convention on nomenclature for DNA cytometry , 1984 .

[8]  I. Taylor,et al.  Clinical and biological significance of aneuploidy in human tumours. , 1984, Journal of clinical pathology.

[9]  M. Oken,et al.  Recurrent chromosomal defects are found in most patients with non-Hodgkin's-lymphoma. , 1984, Cancer genetics and cytogenetics.

[10]  J. Rowley,et al.  Prognostic implications of karyotype and morphology in patients with non‐Hodgkin's lymphoma , 1983, International journal of cancer.

[11]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  B. Barlogie,et al.  Flow cytometry in clinical cancer research. , 1983, Cancer research.

[13]  A. Look,et al.  Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. , 1982, Blood.

[14]  B. Nathwani,et al.  Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia , 1982, Cancer.

[15]  B. Clarkson,et al.  Treatment of advanced diffuse histiocytic lymphoma: An analysis of prognostic variables , 1982, Cancer.

[16]  R. Fisher,et al.  Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. , 1981, Blood.

[17]  R. E. Cunningham,et al.  Dual parameter flow cytometry studies in human lymphomas. , 1980, The Journal of clinical investigation.

[18]  J Schumann,et al.  Cellular DNA content as a marker of neoplasia in man. , 1980, The American journal of medicine.

[19]  R. Braylan,et al.  Flow analysis of DNA content and cell size in non-Hodgkin's lymphoma. , 1980, Cancer research.

[20]  V. Ll.  Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei. , 1977 .

[21]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[22]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.